Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanadrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanadrel SCHEMBL23858317 | 1.00 | PABPC1 (0.45) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| Guanadrel SCHEMBL23858327 | 0.98 | PABPC1 (0.44) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| Guanadrel SCHEMBL23858296 | 0.93 | PABPC1 (0.40) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| Guanadrel SCHEMBL1649864 | 0.93 | PABPC1 (0.40) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL8637708 | 0.75 | GAA (0.50) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL8192982 | 0.74 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL8325616 | 0.74 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL1487109 | 0.74 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL714617 | 0.74 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL8200760 | 0.74 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12396998-B2 | Treatment for heart failure with preserved ejection fraction with guanethidine and guanadrel | M2SP LLC (US) | 2025-08-26 | — | — | US | claimed |
| EP-4590307-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC (US) | 2025-07-30 | — | — | EP | claimed |
| US-20250177415-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC | 2025-06-05 | — | — | US | claimed |
| US-20250177416-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC | 2025-06-05 | — | — | US | claimed |
| WO-2024064630-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC (US) | 2024-03-28 | — | — | WO | claimed |
| US-20210198741-A1 | IDENTIFICATION OF SPATIAL BIOMARKERS OF HEART DISORDERS AND METHODS OF USING THE SAME | 10X GENOMICS, INC. | 2021-07-01 | — | — | US | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-2941252-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | Catabasis Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | claimed |
| WO-2014107730-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | WO | claimed |
| US-20070104782-A1 | Modified release tablet formulations with enhanced mechanical properties | SUPERNUS PHARMACEUTICALS INC. | 2007-05-10 | — | — | US | claimed |
| WO-2007016350-A2 | MODIFIED RELEASE TABLET FORMULATIONS WITH ENHANCED MECHANICAL PROPERTIES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | SLC6A2 427/4885PABPC1 401/4885CTDSP1 4702/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | SLC6A2 227/4885PABPC1 3944/4885CTDSP1 4515/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | SLC6A2 210/4885PABPC1 2252/4885CTDSP1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.